Dr. Jun Zhou 周军
Chief Physician
Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of digestive system tumors, especially chemotherapy, targeted immunotherapy, and photodynamic therapy for liver, gallbladder, and pancreatic cancers.
Dr. Zhou is a Chief Physician at Peking University Cancer Hospital with years of experience in medical oncology and digestive endoscopy for malignant digestive tumors. Dr. Zhou has published over ten articles in domestic and international journals and participated in dozens of multi-center clinical trials.
Name order: in Chinese the family name comes first (Zhou Jun). Papers usually list the name as Jun Zhou or Zhou J.
Selected publications
86 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Sci, 2026 (first author): Efficacy and Safety of DVDMS-Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial. PubMed 42700165
- Curr Med Chem, 2025 (senior author): Identification of Key Genes and Pathways in Lenvatinib-resistant Hepatocellular Carcinoma using Bioinformatic Analysis and Experimental Validation. PubMed 39838683
- Chin J Cancer Res, 2024 (first author): Epidemiology of biliary tract cancer in China: A narrative review. PubMed 39539810
- World J Gastroenterol, 2024 (senior author): Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. PubMed 39193574
- Hepatology, 2023 (first author): Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. PubMed 35491432
- J Sep Sci, 2021 (first author): A validated HPLC-MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. PubMed 34472219
- Hepatobiliary Surg Nutr, 2021 (senior author): Interpretation of NCCN guidelines for hepatobiliary tumors V3 update in 2021. PubMed 34760973
- Oncol Rep, 2021 (first author): GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration. PubMed 33846801
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion